Progress toward a vaccine for extraintestinal pathogenic E. coli (ExPEC) II: efficacy of a toxin-autotransporter dual antigen approach
Infection and Immunity · 2024
DOI: 10.1128/iai.00440-23 ↗Kurz gefasst
Fachartikel in der Zeitschrift Infection and Immunity, 2024. Verfasst von Yikun Xing und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas, USA. Hauptthemen laut MEDLINE: Extraintestinal Pathogenic Escherichia coli, Escherichia coli Infections, Hemolysin Proteins, Escherichia coli Proteins. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 140 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, HHS | NIH | National Institute of Allergy and Infectious Diseases.
Abstract (Originalsprache)
Extraintestinal pathogenic Escherichia coli (ExPEC) is a leading cause of worldwide morbidity and mortality, the top cause of antimicrobial-resistant (AMR) infections, and the most frequent cause of life-threatening sepsis and urinary tract infections (UTI) in adults. The development of an effective and universal vaccine is complicated by this pathogen’s pan-genome, its ability to mix and match virulence factors and AMR genes via horizontal gene transfer, an inability to decipher commensal from pathogens, and its intimate association and co-evolution with mammals. Using a pan virulome analysis of >20,000 sequenced E. coli strains, we identified the secreted cytolysin α-hemolysin (HlyA) as a high priority target for vaccine exploration studies. We demonstrate that a catalytically inactive pure form of HlyA, expressed in an autologous host using its own secretion system, is highly immunogenic in a murine host, protects against several forms of ExPEC infection (including lethal bacteremia), and significantly lowers bacterial burdens in multiple organ systems. Interestingly, the combination of a previously reported autotransporter (SinH) with HlyA was notably effective, inducing near complete protection against lethal challenge, including commonly used infection strains ST73 (CFT073) and ST95 (UTI89), as well as a mixture of 10 of the most highly virulent sequence types and strains from our clinical collection. Both HlyA and HlyA-SinH combinations also afforded some protection against UTI89 colonization in a murine UTI model. These findings suggest recombinant, inactive hemolysin and/or its combination with SinH warrant investigation in the development of an E. coli vaccine against invasive disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas, USA.
- TAILOR Labs, Vaccine Development Group, Baylor College of Medicine, Houston, Texas, USA.
- Alkek Center for Metagenomics and Microbiome Research, Baylor College of Medicine, Houston, Texas, USA.
ORCID-Profile: Yikun Xing, Kathryn A Patras, Anthony W Maresso
Förderung
- NIAID NIH HHS
- HHS | NIH | National Institute of Allergy and Infectious Diseases
Zitieren
APA
Xing, Y., Clark, J. R., Chang, J. D., Zulk, J. J., Chirman, D. M., Piedra, F. A., Vaughan, E. E., Hernandez Santos, H. J., Patras, K. A., & Maresso, A. W. (2024). Progress toward a vaccine for extraintestinal pathogenic E. coli (ExPEC) II: efficacy of a toxin-autotransporter dual antigen approach. Infection and Immunity. https://doi.org/10.1128/iai.00440-23
Vancouver
Xing Y, Clark JR, Chang JD, Zulk JJ, Chirman DM, Piedra FA, et al. Progress toward a vaccine for extraintestinal pathogenic E. coli (ExPEC) II: efficacy of a toxin-autotransporter dual antigen approach. Infection and Immunity. 2024. doi:10.1128/iai.00440-23
BibTeX
@article{Xing2024,
author = {Xing, Yikun and Clark, Justin R and Chang, James D and Zulk, Jacob J and Chirman, Dylan M and Piedra, Felipe-Andres and Vaughan, Ellen E and Hernandez Santos, Haroldo J and Patras, Kathryn A and Maresso, Anthony W},
title = {Progress toward a vaccine for extraintestinal pathogenic E. coli (ExPEC) II: efficacy of a toxin-autotransporter dual antigen approach},
journal = {Infection and Immunity},
year = {2024},
doi = {10.1128/iai.00440-23}
}
EUVIMED